This thesis provides insights regarding pharmacokinetics and -dynamics of TNF inhibitors in patients with PsA and gives more knowledge as to why some patients have a poorer clinical response or do not respond at all. Furthermore, it is important to understand why patients fail or have a shorter drug survival and thereby potentially providing clinicians ways to optimise treatment in order to reach the target of remission or minimal disease activity. Finally, this thesis demonstrates that applying knowledge obtained in one area can be of use in other areas. Knowledge about clinical microbiology and rheumatic patients resulted in an opportunity and interest to investigate SARS-CoV-2 and adherence to isolation measures in rheumatic patients. Finally, the experience with enzyme linked immunoassays to detect immune responses against biopharmaceutical drugs was used to develop a sensitive bridging assay for detecting antibodies against SARS-CoV-2.
|Qualification||Doctor of Philosophy|
|Award date||23 Jun 2021|
|Publication status||Published - 24 Jun 2021|